ライフサイエンスコーパス: viremia

1 developed and run twice per week to monitor viremia.

2 rt review of all patients with confirmed HCV viremia.

3 s in viremia compared with those with stable viremia.

4 humans, CD8 T cells proliferated during CMV viremia.

5 g virus can cause failure of ART to suppress viremia.

6 nces from plasma of 8 donors with persistent viremia.

7 scription during ART-mediated suppression of viremia.

8 nduced CD4(+) T cell loss despite persistent viremia.

9 nt was 578 cells/muL, and 94% had controlled viremia.

10 nd fewer Triplex-vaccinated patients had CMV viremia.

11 d cryptococcal meningitis had detectable CMV viremia.

12 sponse that protected from detectable plasma viremia.

13 prior to start of ART were risk factors for viremia.

14 ernative for the quantification of low-level viremia.

15 he CNS, which may eventually lead to rebound viremia.

16 d pathogenic SIV challenge despite high peak viremia.

17 ad considerably lower Friend retrovirus (FV) viremia.

18 alleles longitudinally after control of peak viremia.

19 tivation than those with detectable residual viremia.

20 males displaying significantly reduced acute viremia.

21 l immunodeficiency and persistent SARS-CoV-2 viremia.

22 ut cystitis (asymptomatic), 58 (40%) had any viremia.

23 plant or for 16 weeks after the onset of ADV viremia.

24 disease, viral shedding, and cell-associated viremia.

25 cquisition but manifested partial control of viremia.

26 mouse spleens in parallel with the onset of viremia.

27 gs lower than expected based on pretreatment viremia.

28 CD4 was 578 cells/mL, and 94% had controlled viremia.

29 (>1000 copies/mL) compared with no detected viremia.

30 to men, contributing to lower initial plasma viremia.

31 is followed by a long period of undetectable viremia.

32 d with delayed SIV acquisition and decreased viremia.

33 samples from patients with concurrent HHV-6B viremia.

34 esponses were also correlated with decreased viremia.

35 f viral replication before detectable plasma viremia.

36 ere significantly associated with high-grade viremia.

37 hutoff, diminished EEEV's ability to develop viremia.

38 ose of letermovir experienced an increase of viremia.

39 V-1 DNA, which is capable of contributing to viremia.

40 icular lymphoma with protracted COVID-19 and viremia.

41 ted modestly but significantly reduced acute viremia.

42 r the effects of interventions on persistent viremia.

43 vival rates among those with and without CMV viremia.

44 all individuals with HIV who have detectable viremia.

45 levels of HBV antigens, HBV replication, and viremia (1-3 log(10) reduction) compared to mice given c

46 stinterruption time points before detectible viremia (1.65 mean relative increase, P = .005).

47 RT-naive; 30 ART-treated with non-detectable viremia; 30 elite controllers; 30 viremic controllers; a

48 lop BK viruria (66.6% vs 7.8%; P < .001) and viremia (66.6% vs 8.9%; P < .001) with a shorter time to

49 latacept presented a higher incidence of CMV viremia, a higher rate of first-line treatment failure a

50 e system helps prevent clinically detectable viremia, a portrait of the factors that induce reactivat

51 tease Inhibitor Era (SCOPE) cohort showed no viremia above the level of quantification in the first 1

52 cell reactivation event leads to observable viremia after a period of exponential viral growth.

53 ntigen expression, but not mice with reduced viremia after administration of entecavir, developed pol

54 acaques had no demonstrable effect on plasma viremia after cART interruption.

55 Screening for BKPyV viremia after HCT identifies asymptomatic patients at ri

56 amu-B*08 spontaneously control chronic-phase viremia after infection with the pathogenic simian immun

57 retroviral [ART] therapy; n = 2 with rebound viremia after stopping ART), who provided serial blood s

58 s (HIV) are limited to partial reductions in viremia after the establishment of productive infection.

59 her peak HHV-6 viral load (p=0.006) vs HHV-6 viremia alone.

60 tfeeding and cesarean delivery in women with viremia also reduced risk of transmission and that prena

61 with HDV viremia compared with those without viremia, although the latter was not statistically signi

62 ity rates were 40% (23/58) in those with CMV viremia and 21% (11/53) in those without CMV viremia (ha

63 itivity, including 233 patients with HDV RNA viremia and 91 without HDV viremia at baseline, were ret

64 lated with the occurrence of recipient BKPyV viremia and BKPyVAN in the first year after KTx.

65 0(3) PFU) challenge, though they experienced viremia and body weight loss.

66 in the next RM, resulting in extremely high viremia and CD4(+) T-cell loss.

67 Viremia and clinical evidence of infection were present

68 e by 12 months, defined as CMV syndrome (CMV viremia and clinical or laboratory findings) or end-orga

69 We report on predictors of adenovirus (ADV) viremia and correlation of ADV viral kinetics with morta

70 on is characterized by persistent high-level viremia and defective cellular immunity, including a lac

71 antibodies (bnAbs) effectively lower plasma viremia and delay virus reemergence.

72 nate immune pathway that controls alphavirus viremia and dissemination in vertebrate hosts, ultimatel

73 lowed for escape from clearance and enhanced viremia and dissemination.

74 ype mice, but Prf1-/- mice develop prolonged viremia and fatal HLH.

75 n HIV- men, especially in the setting of HIV viremia and heightened inflammation.

76 ented with failure to thrive, persistent EBV viremia and hepatitis, pneumocystis jirovecii pneumoniti

77 n antiretroviral therapy with suppressed HIV viremia and high CD4 T cell counts, the efficacy of conv

78 s were associated with detectable SARS-CoV-2 viremia and hypoxemia (both P<0.001).

79 ddress the correlation between the course of viremia and immune reconstitution.

80 l microbiome of males and females with acute viremia and immune responses associated with protection

81 In 6 (12.5%) of 48 patients with high-level viremia and in 3 (21.4%) of 14 with BKPyVAN, this respec

82 SK9 levels in patients with dengue with high viremia and increased severity of plasma leakage.

83 coordinator navigated individuals to confirm viremia and link to substance use treatment or primary c

84 ted by establishing, through delayed time to viremia and phylogenetic analysis of plasma virus, that

85 ofoundly delayed, prolonging the duration of viremia and potential for transmission.

86 AaVA-1-deficient mosquitoes present a lower viremia and prolonged survival.

87 neutralizing antibodies (bnAbs) can suppress viremia and protect against HIV infection.

88 irus (VZV), developed primary infection with viremia and rash, which resolved upon clearance of virem

89 Patterns of viremia and reactivation are influenced by the host immu

90 to HIV-1-infected humanized mice suppressed viremia and selected for viruses lacking the N448(gp120)

91 ignificantly lower levels of residual plasma viremia and SIV-DNA content in blood and tissues.

92 nce need to be defined to effectively target viremia and the HIV-1 reservoir.FUNDINGNational Cancer I

93 n I/III linker region and protects mice from viremia and viral dissemination following ZIKV or DENV-2

94 ricted ZIKV that precluded the generation of viremia and viral dissemination to peripheral organs.

95 rudescent clinical disease, but intermittent viremia and virus shedding were detected up to day 60 po

96 on increased prior to the first detection of viremia and was nearly tripled in subjects with high lev

97 The CS-CMVi was defined as CMV viremia and/or disease necessitating antiviral therapy.

98 ever and viremia, and core body temperature, viremia, and blood cell and chemistry panels were monito

99 of CHIKV previously shown to cause fever and viremia, and core body temperature, viremia, and blood c

100 m is associated with mycobacterial IRIS, HIV viremia, and Glut-1 expression on CD4+ cells and monocyt

101 low rate of CD4 decline, low to undetectable viremia, and high neutralizing antibody titers throughou

102 ropositivity, time spent with detectable HIV viremia, and injection drug use.

103 s had higher CD4 T cell counts, lower plasma viremia, and SIV-DNA content in blood and LN compared to

104 d in 36 (9%) recipients, reduced the risk of viremia approximately fivefold (hazard ratio, 0.18; 95%

105 earts and lungs from donors with hepatitis C viremia are typically not transplanted.

106 Diagnostic tools to establish the cause of viremia are urgently needed to accelerate clinical decis

107 SARS-CoV-2 viral loads, especially plasma viremia, are associated with increased risk of mortality

108 hese cells significantly reduced acute-phase viremia, as well as accelerated HIV suppression in the p

109 ued ART for >7 months, and controlled plasma viremia at <10(4) copies/ml for up to 8 months after ATI

110 HHV-6 viremia at any level developed in 42% (40/96).

111 ents with HDV RNA viremia and 91 without HDV viremia at baseline, were retrospectively studied, with

112 ], 1.292-2.323, per 10-kg increment) and HIV viremia at the time of vaccination (aOR, 2.922; 95% CI,

113 atment levels to sustained suppression, with viremia being 0.5 to 5 logs lower than expected based on

114 In addition to suppressing viremia, bNAbs may have T cell immunomodulatory effects

115 he HIV-1 reservoir have resulted in blips of viremia but not in a decrease in the size of the latent

116 ients (adult 81.7%), 51 (8.7%) developed ADV viremia by D +100.

117 Measurements included RMD levels, plasma viremia by single copy HIV-1 RNA assay, HIV-1 DNA, cell-

118 rus (SHIV) model to determine whether plasma viremia can be controlled after ART interruption.

119 These results indicate that nonsuppressible viremia can be due to expanded clones of infected CD4+ T

120 tpartum in women with concurrent declines in viremia compared with those with stable viremia.

121 d higher, respectively, in patients with HDV viremia compared with those without viremia, although th

122 t not males, exhibited lower levels of acute viremia, compared to same-sex controls.

123 From 2015 to 2018, 102 patients with viremia completed intake.

124 After detection of viremia, confirmatory testing took 29 weeks (IQR: 16-54)

125 , 99% [670/679] RNA performed, 64% [433/679] viremia confirmed) and 85% linked to care (368/433).

126 , 71% [299/419] RNA performed, 80% [241/299] viremia confirmed) and 93% linked to care (225/241).

127 eated with ART for 12 months and with plasma viremia consistently below 3 copies/ml.

128 In contrast, persisting viremia continued to drive T cell activation and PD-1 an

129 8 ratios, suggesting that factors other than viremia contribute to immunosuppression and wasting synd

130 e microbiome on vaccine-induced immunity and viremia control require further study by microbiome tran

131 To better understand the characteristics of viremia control, we evaluated gene expression of purifie

132 for cross-reactive central memory T cells in viremia control.

133 e microbiome on vaccine-induced immunity and viremia control.

134 Viremia controllers had greater diversity of HCMV-specif

135 Donor viremia conveys an early risk which appears to subside o

136 ific immune responses may play a role in the viremia-dependent pharmacokinetics.

137 antiviral therapy for early asymptomatic CMV viremia detected by surveillance testing), has not previ

138 consecutive negative tests a week apart) for viremia detected by weekly plasma CMV polymerase chain r

139 Fifteen (29%) patients with ADV viremia died by D +180; 8 of 15 (53%) died from ADV.

140 e acid-pDC-IFN signaling axis, which affects viremia, dissemination, and potentially transmission.

141 with impaired CMV-CD8+ TIC score had longer viremia duration (42.4 days vs 18.8 d; P < 0.001).

142 As lower viremia during acute infection is associated with reduce

143 ce robust and persistent induction of plasma viremia during ART in three in vivo animal models of HIV

144 Protection from virus shedding and viremia during challenge infection in combination with r

145 Recipients developed CMV viremia during the first month post-BMT.

146 led, but 9 patients experienced transient BK viremia during the first year.

147 Viremia, emergence of drug-resistant variants, and quasi

148 d antiretroviral therapy (cART) and there is viremia flare up upon therapy interruption.

149 a and rash, which resolved upon clearance of viremia, followed by the establishment of latency.

150 tibodies that protect from detectable plasma viremia following rechallenge and persist for at least 2

151 evealed from the composition of recrudescing viremia following treatment cessation.

152 uction of progeny capable of causing rebound viremia following treatment interruption.

153 ebound with return to pretreatment set point viremia following treatment interruption.

154 points from 8 donors who had nonsuppressible viremia for more than 6 months.

155 participants in the analysis, aOR of future viremia for participants with TFV-DP <800 and 800 to <16

156 ical ventilation, high-level cytomegalovirus viremia, gram-negative bacteremia, invasive mold infecti

157 (median age 10 years) and found that 18% had viremia >=10 000 copies/mL and 45% had viruria >=109 cop

158 Viremia >=10 000 copies/mL was associated with a higher

159 ntire cohort and asymptomatic subset, having viremia >=10 000 copies/mL was associated with a lower c

160 24 post-HCT) and tested associations of peak viremia >=10 000 or viruria >=109 copies/mL with estimat

161 s nearly tripled in subjects with high level viremia (>1000 copies/mL) compared with no detected vire

162 stimated adjusted odds ratio (aOR) of future viremia (>=20 copies/mL) were compared to the highest TF

163 participants with persistently undetectable viremia had more robust HIV-specific T-cell responses.

164 Participants with HPgV viremia had statistically significantly increased risks

165 viremia and 21% (11/53) in those without CMV viremia (hazard ratio 2.19, 95% confidence interval [CI]

166 oncentrations are associated with SARS-CoV-2 viremia, hypoxemia, and worse outcome.

167 sts in cellular reservoirs that can reignite viremia if antiretroviral therapy (ART) is interrupted.

168 T) recipients with and without HHV-6B plasma viremia, (ii) tumor tissue samples from subjects with la

169 detected in the lung at high concentrations; viremia in 6 of 10 and 5 of 12 patients demonstrated hig

170 o monitor the incidence and treatment of CMV viremia in a Cynomolgus macaque model of bone marrow tra

171 Detection of residual plasma viremia in antiretroviral therapy (ART)-suppressed HIV-i

172 ed robust and persistent induction of plasma viremia in antiretroviral therapy (ART)-treated simian i

173 rovided only partial protection against ZIKV viremia in BALB/c mice.

174 Long-term viremia in chronic HBV patients occurs either spontaneou

175 clinical management of patients experiencing viremia in clinical practice in LMIC.

176 arameters and outcomes associated with HHV-6 viremia in high-risk donor CMV-seropositive and recipien

177 peutic use, even 1-18 alone fully suppressed viremia in HIV-1-infected humanized mice without selecti

178 ent initiation correlated with higher plasma viremia in HIV-45G-infected animals, but not in HIV-WT-i

179 g., chickens), it does not cause significant viremia in humans.

180 rnative to iSCA v2 for quantifying low-level viremia in individuals on ART.

181 erruption almost invariably leads to rebound viremia in infected individuals due to a long-lived late

182 uria is associated with early BK viruria and viremia in kidney transplant recipients.

183 nates through the body via a cell-associated viremia in leukocytes, despite the presence of neutraliz

184 t-versus-host disease were predictors of ADV viremia in multivariate models.

185 d from these time-points failed to result in viremia in naive females inoculated intravaginally.

186 lthough ZIKV vaccines that prevent or reduce viremia in non-pregnant mice have been described, a mate

187 Viremia in serum of Ad AdrA wt-treated mice was reduced

188 It remains unclear whether CMV viremia in severely immunocompromised persons with crypt

189 dly neutralizing antibody Bc1.187 suppressed viremia in vivo in HBV mouse models and led to post-ther

190 , we observed that ZIKV I1404 produced lower viremias in nonpregnant macaques and was a weaker compet

191 blood and mucosa coincident with peak HIV-1 viremia, in a manner associated with emerging microbial

192 In chronically infected animals with viremia initially controlled by combination antiretrovir

193 ant 30 kidneys from deceased donors with HCV viremia into HCV-uninfected recipients, followed by 8 we

194 The magnitude and duration of vertebrate viremia is a critical determinant of arbovirus transmiss

195 Cell-associated viremia is a prerequisite for the most severe disease ou

196 HDV RNA viremia is associated with a 3.8-fold higher risk for li

197 It is unknown whether concurrent CMV viremia is associated with mortality in other AIDS-relat

198 Uncontrolled CMV viremia is associated with specific clusters of memory T

199 patients, of whom 11 (9.6%) of 115 developed viremia late, that is, after the second year posttranspl

200 irrespective of outcome, with persistent HCV viremia leading to sustained upregulation of PD-1 and CT

201 Notably, 9 significantly reduced the viremia level and increased animal survival time in mous

202 ty for glycosaminoglycans (GAGs) and reduced viremia levels and the efficiency of replication in majo

203 sulted in a more pronounced reduction of HIV viremia levels over cART alone, but the effect was not p

204 Residual plasma viremia levels positively correlated with cell-associate

205 , HIV controllers with undetectable residual viremia <0.6 HIV-1 RNA copies/mL had higher CD4+ counts

206 detectable BKPyV-specific T cells and having viremia <10 000 copies/mL, but not cidofovir exposure.

207 Cytomegalovirus (CMV) viremia may be associated with increased mortality in HI

208 Cytomegalovirus (CMV) viremia may be associated with increased mortality in pe

209 against MAYV, and the resultant reduction in viremia may limit the emergence potential of MAYV.

210 Treatment at onset of viremia mitigates peripheral T and B cell dysfunction, l

211 ant CMV infection including asymptomatic CMV viremia (n = 3), CMV syndrome (n = 1), and CMV pneumonit

212 Three recipients developed polyomavirus (BK) viremia near or >10,000 copies/ml that resolved after re

213 Interviews and assessments of recurrent HCV viremia occurred at 6-month intervals for up to 24 month

214 Viremia occurred in 19.8% (20,766/104,719) of patients d

215 rvoir in resting CD4(+) T cells, and rebound viremia occurs following treatment interruption.

216 analysis, reveals that CLHIV with detectable viremia on ABC/3TC/LPV/r are more likely to have maintai

217 The level of persistent viremia on ART is generally below the lower limit of qua

218 refore evaluated the long-term impact of HDV viremia on liver-related outcomes in a nationwide cohort

219 RT molecule cocktail did not increase on-ART viremia or cell-associated SHIV RNA in CD4(+) T cells an

220 inority of patients who present with ongoing viremia or central nervous system replication.

221 usions were safe but did not increase plasma viremia or unspliced CA-RNA despite pharmacodynamic effe

222 cantly lower in children with detectable EBV viremia (P = .014).

223 0) and did not differ by the presence of CMV viremia (P = .47).

224 a was associated with earlier onset of HHV-6 viremia (p=0.004), higher HHV-6 AUC (p=0.043), and highe

225 Furthermore, the impact of HDV viremia per se on liver-related outcomes is not really k

226 Follow-up plasma viremia, peripheral blood CD4(+) T cell counts, and lymp

227 s referred by clinicians for nonsuppressible viremia (plasma HIV-1 RNA above 40 copies/mL) despite re

228 ted controls became infected with high-level viremia postchallenge.

229 on of individuals with undetectable residual viremia (pre-ART vs after 24-48 weeks of ART: 19% vs 94%

230 ogeneic HCT, we quantified BKPyV viruria and viremia (pre-HCT and at Months 1-4, 8, 12, and 24 post-H

231 Maternal viremia predicts fetal infection and neonatal outcome.

232 people living with HIV (PWH) with suppressed viremia (predominantly men who have sex with men (MSM))

233 onstrate consistent early peak and set point viremia, rapid declines in viremia to undetectable plasm

234 HIV-specific T cell responses, low-level HIV viremia, rca-RNA, and the frequency of resting CD4(+) T-

235 Management of CMV required treatment before viremia reached 10 000 copies/mL; otherwise clinical sym

236 Our results showed that viremia rebounded despite the absence of HIV-1 adaptatio

237 Overall, lower plasma viremia, reduced cell-associated SIV-DNA, and preserved

238 014, as compared with placebo, in abrogating viremia related to the administration of live yellow fev

239 However, its value as a predictor of future viremia remained unknown.

240 In some individuals, viremia remains detectable despite adherence to ART and

241 CMV events (CMV DNA level >=1250 IU/mL, CMV viremia requiring antiviral treatment, or end-organ dise

242 bound and a lower maximum decrease in plasma viremia, respectively, after treatment with a V3 loop bn

243 Interestingly, plasma viremia returned to predepletion levels even when periph

244 hile CRF02_AG-infected animals showed higher viremia, subtype-B-infected animals showed significantly

245 f this association depended on the degree of viremia, such that in HIV+ men with undetectable VL, adj

246 BACKGROUNDHIV-1 viremia that is not suppressed by combination antiretrov

247 Clearance of low-level viremia that persists in most HIV-1-positive individuals

248 f 2 mg per kilogram had detectable YF17D-204 viremia; these participants remained aviremic throughout

249 l ASFV-G-DeltaI177L-infected animals had low viremia titers, showed no virus shedding, and developed

250 port its use for quantifying residual plasma viremia to study the latent HIV reservoir and cure inter

251 , including prospective monitoring for BKPyV viremia to test virus-specific T cells to prevent or tre

252 eak and set point viremia, rapid declines in viremia to undetectable plasma titers following cART ini

253 Incidence and persistence of CMV viremia under belatacept vs tacrolimus were compared.

254 ical suppression over time and management of viremia under programmatic conditions.

255 d viral reservoir that gives rise to rebound viremia upon cessation of ART.

256 days in the PET group were tested for HHV-6 viremia using a real-time quantitative PCR.

257 be overcome by novel methods to monitor CMV viremia using self-testing platforms.

258 the detection and quantitation of low-level viremia using the following two adaptions of the automat

259 In addition, viremia values in ASFV-G-Delta8DR do not differ from tho

260 urally, as evidenced by occasional low-level viremia ("viral blips") during antiretroviral treatment

261 opsy proven rejection) and infection events (viremia/viral infections).

262 Viremia was achieved in 3/3 FP ZIKV-infected dams and 2/

263 Enbrel-treated wt mice, a reduction of serum viremia was achieved-an observation that was lost in ant

264 CMV viremia was associated with an over 2-fold higher mortal

265 Clearing viremia was associated with detectable BKPyV-specific T

266 Concurrent HHV-6 and CMV viremia was associated with earlier onset of HHV-6 virem

267 ving valganciclovir as PET, high-grade HHV-6 viremia was associated with increased age and critical-i

268 Of these, 28 (3.6%) tested positive, and viremia was confirmed in all who underwent repeat testin

269 Adenovirus viremia was defined as >=2 consecutive viral loads (VLs)

270 diversity in the FGT and plasma by the time viremia was detectable.

271 Residual viremia was dominated by identical HIV-1 RNA sequences t

272 High-grade viremia was independently associated with biopsy-proven

273 Plasma viremia was measured for 7 to 10 weeks, and single-genom

274 Residual plasma viremia was measured using the integrase single-copy ass

275 Viremia was observed at 48 hours after the infusion in 2

276 BKPyV viremia was observed in 115 (36.7%) of 311 patients, of

277 The induction of detectable plasma viremia was observed in three out of five RMs, with the

278 Viremia was prevalent among patients who unofficially tr

279 Clinical management in response to viremia was profoundly delayed, prolonging the duration

280 However, peak viremia was significantly reduced in infected vaccinees

281 was monitored through flow cytometry and CMV viremia was tracked via quantitative polymerase chain re

282 k ADV VL through 16 weeks after onset of ADV viremia were explored as predictors of mortality in Cox

283 Despite these effects, no changes in plasma viremia were observed after cART interruption.

284 No significant changes in viremia were observed in Cohorts 1-4 compared to placebo

285 linical signs and death associated with ZIKV viremia were observed in mice.

286 bsets, cytokine and chemokine secretion, and viremia, were assessed.

287 t M-tropic variants can appear in rebounding viremia when treatment is interrupted.

288 We observed the induction of plasma viremia, which correlated with the efficacy of the CD8 d

289 High doses of ganciclovir resolved the viremia, which could subsequently be controlled with val

290 re infected with HIV-1 with suppressed blood viremia, while receiving bNAb therapy during ART interru

291 Remarkably, transient suppression of RHV viremia with a direct-acting antiviral led to the primin

292 l studies, assessing the association of HPgV viremia with adult lymphomas.

293 ysis supports a positive association of HPgV viremia with lymphoma risk, overall and for the major ly

294 Among patients with HDV viremia with no baseline cirrhosis, the cumulative risk

295 p with CMV, risk factors and impact of HHV-6 viremia with outcomes through 12 months post-transplant.

296 tudies have suggested an association of HPgV viremia with risk of lymphomas.

297 show that ZIKV-rectal inoculation results in viremia with subclinical infection.

298 ctable in six of 20 participants with plasma viremia, with no group changes in CSF immune activation

299 100% of the participants tested negative for viremia within 48 hours after infusion.

300 gnosis was rather poor for patients with HDV viremia without cirrhosis at baseline, but it was nevert